{"id":"felodipine-ramipril","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Edema"},{"rate":"1-5%","effect":"Dizziness"},{"rate":"1-5%","effect":"Headache"},{"rate":"1-5%","effect":"Nausea"},{"rate":"1-5%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1168","moleculeType":"Small molecule","molecularWeight":"416.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Felodipine works by blocking the influx of calcium ions into smooth muscle cells, causing vasodilation and a decrease in blood pressure. Ramipril, on the other hand, inhibits the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure.","oneSentence":"Felodipine is a calcium channel blocker that relaxes blood vessels, while ramipril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:20.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00367939","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":132},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00841880","phase":"PHASE4","title":"China Medical University Hospital (CMUH) Triapin Listing","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-01","conditions":"Hypertension","enrollment":49},{"nctId":"NCT00507845","phase":"PHASE4","title":"Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-06","conditions":"Hypertension","enrollment":271},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00679653","phase":"PHASE3","title":"Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-02","conditions":"Obesity, Hypertension","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"felodipine/ramipril","genericName":"felodipine/ramipril","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Felodipine is a calcium channel blocker that relaxes blood vessels, while ramipril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure. Used for Hypertension, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}